While they are still early and immature, data presented at the American Society of Clinical Oncology meeting, as well as research highlighted in an educational session, provide a glimpse at where next-generation cell therapies could fit into oncology treatment paradigms and how they can be engineered to overcome limitations. That may even include replacing the autologous chimeric antigen receptor T-cell (CAR-T) cell therapies already on the market, as well as greatly increasing cell therapies’ availability in developing countries.
Companies like Allogene Therapeutics Inc., Fate Therapeutics, Inc. and others presented clinical data at the ASCO meeting, which...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?